MACAU DAILY TIMES 澳門每日時報

Top Menu

  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia

Main Menu

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
logo
FOUNDER & PUBLISHER Kowie Geldenhuys
EDITOR-IN-CHIEF Paulo Coutinho
Macau,

MACAU DAILY TIMES 澳門每日時報

  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • ‘Madden’ biopic can’t find a playbook to stick with

  • Juksunchae: A Study in Precision and Contemporary Korean Cuisine

  • Reframing the “Hundreds of Flavors”: Chiang and Ho at Zi Yat Heen

  • Mexico’s Catholic street DJs turn annual pilgrimage into a party

  • A van Gogh with a complex past sells for a record $190 million at auction

  • Nvidia and the risks of CEO misconduct

Business
Home›Business›Samsung looks beyond smartphones to next-gen biologics

Samsung looks beyond smartphones to next-gen biologics

By -
Wednesday, May 17, 2017
115
0

A worker mops the floor of a bioreactor hall at the Samsung Biologics Co. plant 3 under construction in the Songdo district in Incheon

The Samsung brand is best known for its smartphones and wide-screen TVs. Yet behind the scenes, the conglomerate is also making a name as a contract manufacturer of complex medicines to treat diseases like cancer.

On a piece of reclaimed land along the western coast of South Korea, Samsung BioLogics Co. is building a USD740 million factory that will give it the capacity to become the No. 1 producer by volume of a class of drugs called biologics, many of which are derived from mammal cells.

The Samsung group diversified into the pharmaceutical sector in 2011. Now, it’s mobilizing its expertise in semiconductor making and engineering know-how to make the way biologics are produced on behalf of Big Pharma more efficient. The market for biologic medicines, which are used for everything from cancer to arthritis, is projected to exceed $223.7 billion by 2021, according to a Bloomberg Intelligence analysis.

Being a force in biologics is crucial to Samsung – and South Korea. Galaxy smartphones and other consumer electronics face intense competition from Apple Inc. and Chinese brands such as Huawei Technologies Co., and the chaebol is grappling with the arrest of de facto leader Jay Y. Lee in a scandal that brought down the country’s former president. Meanwhile, the broader economy needs new industries as shipbuilding and heavy manufacturing slow.

If the past 40 years of global economic growth were fueled by technology, said Kim Tae-han, chief executive officer of Samsung BioLogics, the next will be fueled by where that converges with health care.

Biologic drugs are grown from cells. That necessitates a more complex manufacturing process than typical pills – a mixture of chemicals – but makes biologics more effective and capable of being targeted toward certain diseases.

Samsung already is a contract manufacturer for some blockbuster drugs, including for Switzerland’s Roche Holding AG and the U.S.’s Bristol-Myers Squibb Co. It will take three years for the factory to ramp up to full capacity after being completed this year and opening at the end of 2018.

Globally, the drug industry produces 4 million liters of biologic drugs a year, and that’s projected to double by 2030. With its new plant, Samsung BioLogics is positioning itself to double its market share. Shares are up 24 percent this year to 187,000 won. That compares with a 13 percent increase in the benchmark Kospi index.

Samsung and other companies in the sector have benefited from the Korean government’s support of biopharmaceutical businesses. The Incheon Free Economic Zone offered Samsung BioLogics the factory land for 50 years without rent, the company said. New President Moon Jae-in railed against the chaebol during his campaign, but Samsung said in an email it expected him to boost the biopharmaceutical and health-care industries.

Nevertheless, Samsung faces some formidable competitors, who are also expanding. Switzerland’s Lonza Group AG and Germany’s Boehringer Ingelheim GmbH have long histories in the biologics contract manufacturing business, and Japan’s Fujifilm Holdings Corp. also entered the business. MDT/Bloomberg

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Print (Opens in new window) Print

Like this:

Like Loading…

Related

Previous Article

Corporate bits | MGM Macau introduces new ...

Next Article

Goldman Sachs builds China financial-stress index

Related articles More from author

  • Business

    Airlines in Southeast Asia may defer plane deliveries

    Monday, February 15, 2016
    By -
  • Business

    Corporate Bits | Sands China receives awards from Macau green Hotel award

    Tuesday, June 26, 2018
    By -
  • Business

    Corporate bits | Boutique SPA at the Parisian Macao given award

    Tuesday, July 25, 2017
    By -
  • Business

    Malaysia | Central bank Governor said to have offered to resign

    Wednesday, June 6, 2018
    By -
  • Business

    Toyota agrees to pay USD200m to China dealers, group says

    Thursday, February 5, 2015
    By -
  • Business

    Corporate Bits | Sands holds benediction ceremonies for its dragon boat teams

    Friday, May 20, 2016
    By -

Leave a reply Cancel reply

You must be logged in to post a comment.

  • Daily Edition

    Thursday, June 28, 2018 – edition no. 3077

  • World

    This Day in History | 1997 – Dawn of Scottish parliament

  • World

    Kim vows full support for Russian ‘sacred fight’ after viewing launchpads with Putin

DAILY EDITION

Friday, November 20, 2026 – edition no. 5079
Friday, November 20, 2026 – edition no. 5079

Greater Bay

MDT MACAU GRAND PRIX SPECIAL

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Timeline

  • Friday, November 20, 2026

    ‘Madden’ biopic can’t find a playbook to stick with

  • Friday, November 20, 2026

    Juksunchae: A Study in Precision and Contemporary Korean Cuisine

  • Friday, November 20, 2026

    Reframing the “Hundreds of Flavors”: Chiang and Ho at Zi Yat Heen

  • Friday, November 20, 2026

    Mexico’s Catholic street DJs turn annual pilgrimage into a party

  • Friday, November 20, 2026

    A van Gogh with a complex past sells for a record $190 million at auction

  • Friday, November 20, 2026

    Nvidia and the risks of CEO misconduct

  • Friday, November 20, 2026

    Friday, November 20, 2026 – edition no. 5079

  • Thursday, November 19, 2026

    The Ultimate Holiday Spread: Bring the Chef’s Table Home

  • Thursday, November 19, 2026

    Xi backs global bay area association and calls for freer Asia-Pacific trade

  • Thursday, November 19, 2026

    President Marcos Jr has Jollibee fried chicken delivered to Trump for a late-night snack

Extra Times

Drive InExtra Times

‘Madden’ biopic can’t find a playbook to stick with

Which play to run is a question that can bedevil any football coach, and it’s also what dooms David O. Russell’s fumbled biopic “Madden.” “Madden” may sport an all-star cast ...
  • Juksunchae: A Study in Precision and Contemporary Korean Cuisine

    By Irene Sam, MDT
    Friday, November 20, 2026
  • Reframing the “Hundreds of Flavors”: Chiang and Ho at Zi Yat Heen

    By -
    Friday, November 20, 2026
  • Three chefs. One horizon. Six Michelin stars

    By Irene Sam, MDT
    Friday, November 13, 2026
  • James Gray delivers a milestone crime drama in ‘Paper Tiger’

    By MDT/AP
    Friday, November 13, 2026
  • Recent

  • Popular

  • ‘Madden’ biopic can’t find a playbook to stick with

    By MDT/AP
    Friday, November 20, 2026
  • Juksunchae: A Study in Precision and Contemporary Korean Cuisine

    By Irene Sam, MDT
    Friday, November 20, 2026
  • Reframing the “Hundreds of Flavors”: Chiang and Ho at Zi Yat Heen

    By -
    Friday, November 20, 2026
  • Mexico’s Catholic street DJs turn annual pilgrimage into a party

    By MDT/AP
    Friday, November 20, 2026
  • A van Gogh with a complex past sells for a record $190 million at ...

    By -
    Friday, November 20, 2026
  • Nvidia and the risks of CEO misconduct

    By -
    Friday, November 20, 2026
  • Friday, November 20, 2026 – edition no. 5079

    By -
    Friday, November 20, 2026
  • Canidrome may have its days numbered, decision in ‘one or two months’

    By Paulo Coutinho, MDT
    Thursday, May 26, 2016
  • Animal Welfare | Macau: Anima slams Canidrome management for avoiding debate

    By -
    Wednesday, May 4, 2016
  • Editorial | Canidoomed

    By Paulo Coutinho, MDT
    Wednesday, June 1, 2016
  • Animal Welfare | Canidrome presented with ultimatum: close or move

    By Daniel Beitler, MDT
    Friday, July 22, 2016
  • Australia regulator cracks down on alleged exportation of dogs to Macau

    By Paulo Coutinho, MDT
    Friday, June 10, 2016
  • Animal rights | Canidrome: Anima in fresh airline negotiations as Canidrome closure looks more likely

    By Daniel Beitler, MDT
    Friday, May 27, 2016
  • USE OF ENGLISH IN MACAU | A ‘de facto’ official language

    By Catarina Pinto
    Monday, July 6, 2015
  • Contact our Administrator
  • Contact our Editor-in-Chief
  • Contacts
  • Our Team
  • Privacy Policy
  • Terms and Conditions
  • Editorial Statute
  • Code of Ethics
COPYRIGHT © MACAU DAILY TIMES 2008-2026. ALL RIGHTS RESERVED
MACAU DAILY TIMES
  • Home
  • Macau
    • Photo Shop
    • Advertorial
  • Interview
  • Greater Bay
  • Business
    • Corporate Bits
  • China
  • Asia
  • World
  • Sports
  • Opinion
    • Editorial
    • Our Desk
    • Business Views
    • China Daily
    • Multipolar World
    • The Conversation
    • World Views
  • Our Team
  • Editorial Statute
    • Code of Ethics
    • Privacy Policy
    • Terms and Conditions
  • Archive
    • PDF Editions
  • Contacts
  • Extra Times
    • Drive In
    • Book It
    • tTunes
    • Features
    • World of Bacchus
    • Taste of Edesia
Loading Comments...

You must be logged in to post a comment.

%d